JP2001503780A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503780A5
JP2001503780A5 JP1998523200A JP52320098A JP2001503780A5 JP 2001503780 A5 JP2001503780 A5 JP 2001503780A5 JP 1998523200 A JP1998523200 A JP 1998523200A JP 52320098 A JP52320098 A JP 52320098A JP 2001503780 A5 JP2001503780 A5 JP 2001503780A5
Authority
JP
Japan
Prior art keywords
compound
formula
recipients
hydrochloride
graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998523200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503780A (ja
JP4004070B2 (ja
Filing date
Publication date
Priority claimed from GBGB9624038.7A external-priority patent/GB9624038D0/en
Application filed filed Critical
Publication of JP2001503780A publication Critical patent/JP2001503780A/ja
Publication of JP2001503780A5 publication Critical patent/JP2001503780A5/ja
Application granted granted Critical
Publication of JP4004070B2 publication Critical patent/JP4004070B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP52320098A 1996-11-19 1997-11-17 1,3―プロパンジオール誘導体の新しい用途 Expired - Fee Related JP4004070B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9624038.7 1996-11-19
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004152002A Division JP2004256554A (ja) 1996-11-19 2004-05-21 1,3−プロパンジオール誘導体の新しい用途

Publications (3)

Publication Number Publication Date
JP2001503780A JP2001503780A (ja) 2001-03-21
JP2001503780A5 true JP2001503780A5 (enExample) 2007-08-30
JP4004070B2 JP4004070B2 (ja) 2007-11-07

Family

ID=10803173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP52320098A Expired - Fee Related JP4004070B2 (ja) 1996-11-19 1997-11-17 1,3―プロパンジオール誘導体の新しい用途
JP2004152002A Pending JP2004256554A (ja) 1996-11-19 2004-05-21 1,3−プロパンジオール誘導体の新しい用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004152002A Pending JP2004256554A (ja) 1996-11-19 2004-05-21 1,3−プロパンジオール誘導体の新しい用途

Country Status (24)

Country Link
US (3) US6274629B1 (enExample)
EP (2) EP1312359B1 (enExample)
JP (2) JP4004070B2 (enExample)
CN (2) CN1146411C (enExample)
AT (2) ATE275947T1 (enExample)
AU (1) AU728420B2 (enExample)
BR (1) BR9713105A (enExample)
CA (1) CA2270952C (enExample)
CZ (1) CZ174999A3 (enExample)
DE (2) DE69730727T2 (enExample)
DK (1) DK1312359T3 (enExample)
ES (2) ES2289041T3 (enExample)
GB (1) GB9624038D0 (enExample)
HU (1) HUP0000343A3 (enExample)
ID (1) ID21568A (enExample)
IL (1) IL129824A (enExample)
NO (1) NO992259L (enExample)
NZ (1) NZ335629A (enExample)
PL (1) PL190348B1 (enExample)
PT (2) PT1312359E (enExample)
RU (1) RU2217136C2 (enExample)
SI (1) SI1312359T1 (enExample)
SK (1) SK284806B6 (enExample)
WO (1) WO1998022100A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457478B1 (en) 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
RU2290196C2 (ru) * 2001-04-20 2006-12-27 Дебиофарм С.А. Модифицированный циклоспорин, который можно использовать в качестве пролекарства, и его применение
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
DE60328161D1 (de) 2002-01-11 2009-08-13 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
NZ592339A (en) 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
CA2778126A1 (en) * 2003-06-24 2005-01-13 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
JP5214966B2 (ja) * 2004-07-30 2013-06-19 ノバルティス アーゲー 2−アミノ−1,3−プロパンジオール化合物およびその類似体の製剤
BRPI0619894B8 (pt) 2005-12-15 2021-05-25 Mitsubishi Tanabe Pharma Corp composto de amina e composição farmacêutica
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6484567B2 (ja) * 2013-03-05 2019-03-13 バイオコン・リミテッドBiocon Limited 2−アミノ−1,3−プロパンジオール化合物およびその塩の製造のための方法
WO2017046345A1 (en) 2015-09-18 2017-03-23 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
BR9206313A (pt) * 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
IL121625A (en) * 1995-12-28 2001-09-13 Welfide Corp Preparation containing 2 - amino - 2 - (-2 (-4-octylphenyl) ethyl) propane - 1, 3, - dial for local topical use
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物

Similar Documents

Publication Publication Date Title
JP2001503780A5 (enExample)
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
GEP20043324B (en) Purine Derivatives
AU684059B2 (en) Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
JP2002531505A5 (enExample)
LU90234I2 (fr) Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine
MY118156A (en) Oral compositions of levosimendan.
JP2002510633A5 (enExample)
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
JP2002519425A5 (enExample)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
JP2002522501A5 (enExample)
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
IL128851A (en) Pharmaceutical composition for lowering the uric acid level in the human body
DE69622739D1 (de) Pharmazeutische zubereitung mit schneller freisetzung
WO2000056315A8 (en) Treatment of pain
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
WO2001026641A3 (en) Morpholinol derivatives for the treatment of obesity
IE38655L (en) Pharmaceutical compositions
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체